

10. The use of Claim 9 wherein the blood cells are the patient's own T lymphocytes.

5 11. The use of Claim 1 or 2 wherein the disorder is selected from the group consisting of atherosclerosis, peripheal vascular disease, congestive heart failure, stroke, myocardial infarction, angina, hypertension, Raynaud's disease, cardiac syndrome X, migraine, ischemic damage, inflammatory bowel disease and graft versus host disease.

10 12. The use of Claim 1 or 2 further comprising administering to a human patient a dosage of apoptotic bodies and/or apoptotic cells comprising from 10,000 to 10,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

15 13. The use of Claim 12 wherein the dosage contains from 500,000 to 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

14. The use of Claim 12 wherein the dosage contains from 1,500,000 to 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram body weight of the patient.

20 15. A method for treatment of or prophylaxis against medical disorders resulting from or involving endothelial dysfunction in a mammalian patient, which comprises administering to the patient an effective amount of apoptotic bodies and/or apoptotic cells.

ADD
B11